相关实验视频
Updated: May 12, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
共同开发一项复杂的干预措施,以减少儿童糖尿病中等护理结果的不平等,针对来自服务不足群体的1型糖尿病儿童
Aidan Searle1, Jessica R Wheeler2, Ian Litchfield3
1NIHR Biomedical Research Centre - Diet and Physical Activity Theme, University of Bristol, Bristol, UK A.J.Searle@bristol.ac.uk.
BMJ open
|May 7, 2025
概括
这项研究共同开发了一项干预措施,以改善糖尿病控制服务不足的儿童和患有糖尿病的年轻人 (CYPD). 该干预包括同行支持,健康指导,家庭支持和医疗保健从业人员培训,以减少健康不平等.
科学领域:
- 公共卫生 公共卫生
- 医疗保健服务研究 医疗服务研究
- 行为科学 行为科学
背景情况:
- 对于来自社会经济和种族群体的糖尿病儿童和青少年 (CYPD) 存在显著的健康结果不平等.
- 现有的干预措施往往无法解决多样化的CYPD人群的复杂,多方面的需求,导致糖尿病管理和未来健康的差异.
- 开发有针对性的干预措施需要一种涉及最终用户的共同设计方法,并遵守复杂干预措施的既定框架.
研究的目的:
- 与年轻人糖尿病患者及其家属共同开发干预措施,以改善贫困人口的糖尿病控制和未来健康结果.
- 减少CYPD不同社会经济和种族群体之间的治疗结果的不平等.
- 遵守医学研究理事会对复杂干预的指导和行为改变的COM-B模型.
主要方法:
- 使用阶段式方法,包括文献评论,与CYPD和护理人员进行半结构面试,并使用COM-B框架进行分析.
- 通过聚焦小组与CYPD和护理人员评估干预组件,并与英格兰各地的医疗保健从业人员 (HCP) 进行调查.
- 使用包括可接受性,可行性,有效性,可负担性,溢出效应和公平性在内的标准来评估组件.
主要成果:
- 共同开发过程确定了四个关键干预要素:加强同行支持/指导,健康和福祉教练,家庭/社区支持和定制的HCP培训.
- 医疗保健工作者培训重点是文化能力,防贫,改善缺乏服务的CYPD的沟通敏感性.
- 干预方案涉及个人,社区和临床层面,整合社会文化背景和支持选项.
结论:
- "糖尿病中的多样性"联合开发工作产生了一项专门针对改善服务不足的CYPD糖尿病护理的干预措施.
- 干预反映了社会文化背景,并在多个层面上提供了可信的支持机制.
- 未来的研究将测试可行性,并在额外的儿科糖尿病中心完善干预方案.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes: Management and Pharmacotherapy
212
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
212
Pathophysiology of Diabetes
813
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
813
Chronic Pancreatitis II: Collaborative Care
49
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
49
Insulin: Dosing Regimen and Adverse Effects
127
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
127

